Genetic landscape of congenital insensitivity to pain and hereditary sensory and autonomic neuropathies.
Lischka A., Eggermann K., Record CJ., Dohrn MF., Laššuthová P., Kraft F., Begemann M., Dey D., Eggermann T., Beijer D., Šoukalová J., Laura M., Rossor AM., Mazanec R., Van Lent J., Tomaselli PJ., Ungelenk M., Debus KY., Feely SME., Gläser D., Jagadeesh S., Martin M., Govindaraj GM., Singhi P., Baineni R., Biswal N., Ibarra-Ramírez M., Bonduelle M., Gess B., Sánchez JR., Suthar R., Udani V., Nalini A., Unnikrishnan G., Junior WM., Mercier S., Procaccio V., Bris C., Suresh B., Reddy V., Skorupinska M., Bonello-Palot N., Mochel F., Dahl G., Sasidharan K., Devassikutty FM., Nampoothiri S., Doriqui MJR., Müller-Felber W., Vill K., Haack TB., Dufke A., Abele M., Stucka R., Siddiqi S., Ullah N., Spranger S., Chiabrando D., Bolgül BS., Parman Y., Seeman P., Lampert A., Schulz JB., Wood JN., Cox JJ., Auer-Grumbach M., Timmerman V., de Winter J., Themistocleous AC., Shy M., Bennett DL., Baets J., Hübner CA., Leipold E., Züchner S., Elbracht M., Çakar A., Senderek J., Hornemann T., Woods CG., Reilly MM., Kurth I.
Congenital insensitivity to pain (CIP) and hereditary sensory and autonomic neuropathies (HSAN) are clinically and genetically heterogeneous disorders exclusively or predominantly affecting the sensory and autonomic neurons. Due to the rarity of the diseases and findings based mainly on single case reports or small case series, knowledge about these disorders is limited. Here, we describe the molecular workup of a large international cohort of CIP/HSAN patients including patients from normally underrepresented countries. We identify 80 previously unreported pathogenic or likely pathogenic variants in a total of 73 families in the >20 known CIP/HSAN-associated genes. The data expand the spectrum of disease-relevant alterations in CIP/HSAN, including novel variants in previously rarely recognised entities such as ATL3-, FLVCR1- and NGF-associated neuropathies and previously under-recognised mutation types such as larger deletions. In silico predictions, heterologous expression studies, segregation analyses and metabolic tests helped to overcome limitations of current variant classification schemes that often fail to categorize a variant as disease-related or benign. The study sheds light on the genetic causes and disease-relevant changes within individual genes in CIP/HSAN. This is becoming increasingly important with emerging clinical trials investigating subtype or gene-specific treatment strategies.